ACS
ARKG icon

Archford Capital Strategies’s ARK Genomic Revolution ETF ARKG Stock Holding History

Archford Capital Strategies’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,764
Closed -$338K – 260
2024
Q1 		$338K Buy
11,764
+267
+2% +$8.03K 0.06% 209
2023
Q4 		$377K Buy
11,497
+3,407
+42% +$92.6K 0.07% 191
2023
Q3 		$225K Sell
8,090
-39
-0.5% -$1.27K 0.05% 252
2023
Q2 		$295K Sell
8,129
-220
-3% -$6.92K 0.06% 245
2023
Q1 		$243K Buy
8,349
+301
+4% +$9.33K 0.05% 251
2022
Q4 		$227K Sell
8,048
-921
-10% -$29.2K 0.05% 254
2022
Q3 		$295K Buy
8,969
+12
+0.1% +$441 0.08% 228
2022
Q2 		$282K Buy
8,957
+261
+3% +$9.13K 0.07% 235
2022
Q1 		$403K Buy
8,696
+595
+7% +$28.4K 0.09% 206
2021
Q4 		$496K Sell
8,101
-2,440
-23% -$169K 0.11% 188
2021
Q3 		$788K Buy
10,541
+412
+4% +$34.6K 0.19% 138
2021
Q2 		$937K Buy
10,129
+14
+0.1% +$1.19K 0.23% 115
2021
Q1 		$914K Buy
10,115
+822
+9% +$81.5K 0.24% 110
2020
Q4 		$984K Buy
9,293
+1,763
+23% +$140K 0.23% 130
2020
Q3 		$480K Buy
7,530
+362
+5% +$21.2K 0.13% 176
2020
Q2 		$374K Buy
+7,168
New +$307K 0.11% 183

Other funds holding ARKG

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Archford Capital Strategies's ARKG Position: Q2 2024 in Review

Archford Capital Strategies sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 11,764 shares — an estimated $338K sold.

Archford Capital Strategies first reported a position in ARKG in Q2 2020 and held it in 16 quarters. The position peaked at $984K in Q4 2020. 262 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

  • Archford Capital Strategies reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
  • Archford Capital Strategies sold 11,764 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $338K.
  • Archford Capital Strategies first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 16 quarters.
  • Archford Capital Strategies's ARK Genomic Revolution ETF position peaked at $984K in Q4 2020.
  • 262 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Archford Capital Strategies's 13F filing for Q2 2024, filed 17 Jul 2024.